10.01.08
Indication: Reduced mortality (in heart failure patients)
Source: European Society of Cardiology Meeting, Munich, Germany—September.
Research: Investigators in this study conducted a randomized, controlled trial of chronic heart failure patients from 357 cardiovascular sites in Italy. Patients received either omega 3 PUFAs (polyunsaturated fatty acids) in a capsule once daily (3494 patients) or placebo (3481 patients).
Results: Approximately 950 patients (27%) in the PUFA group died, compared with just over 1000 in the placebo group (29%)—there was relative risk reduction of 9% in the PUFA group. Further, more patients in the placebo group (2053/59%) died or were admitted to the hospital for cardiovascular reasons compared with the PUFA group (1981/57%)—a relative risk reduction of 8% for the PUFA group. In the end, researchers reported that omega 3 PUFAs were responsible for significantly reducing all-cause mortality and visits to the hospital for cardiovascular reasons.
Source: European Society of Cardiology Meeting, Munich, Germany—September.
Research: Investigators in this study conducted a randomized, controlled trial of chronic heart failure patients from 357 cardiovascular sites in Italy. Patients received either omega 3 PUFAs (polyunsaturated fatty acids) in a capsule once daily (3494 patients) or placebo (3481 patients).
Results: Approximately 950 patients (27%) in the PUFA group died, compared with just over 1000 in the placebo group (29%)—there was relative risk reduction of 9% in the PUFA group. Further, more patients in the placebo group (2053/59%) died or were admitted to the hospital for cardiovascular reasons compared with the PUFA group (1981/57%)—a relative risk reduction of 8% for the PUFA group. In the end, researchers reported that omega 3 PUFAs were responsible for significantly reducing all-cause mortality and visits to the hospital for cardiovascular reasons.